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Objectives: In previous work we have demonstrated that delivery of low concentra-
tions (250 ppm) of carbon monoxide by means of inhalation to donors, recipients,
or both protects transplanted lungs from ischemia–reperfusion injury (improved gas
exchange, diminished intragraft and systemic inflammation, and retention of graft
vascular endothelial cell ultrastructure). In this study we examined whether delivery
of carbon monoxide to lung grafts in the preservation solution could protect against
lung ischemia–reperfusion injury.
Methods: Orthotopic left lung transplantation was performed in syngeneic Lewis to
Lewis rats. Grafts were preserved in University of Wisconsin solution with or without
(control solution) carbon monoxide at 4C for 6 hours. Carbon monoxide gas (5% or
100%) was bubbled into University of Wisconsin solution at 4C for 5 minutes before
use.
Results: In control animals, ischemia–reperfusion injury resulted in significant dete-
rioration of graft function and was associated with a massive cellular infiltrate 2 hours
after reperfusion. Grafts stored in University of Wisconsin solution with carbon mon-
oxide (5%), however, demonstrated significantly better gas exchange and signifi-
cantly reduced intragraft inflammation (reduced inflammatory mediators and
cellular infiltrate). Experiments demonstrated that the protective effects afforded by
100% University of Wisconsin solution with carbon monoxide were not as potent
as those of 5% University of Wisconsin solution with carbon monoxide.
Conclusions: This study demonstrates that 5% carbon monoxide as an additive to the
cold flush/preservation solution can impart potent anti-inflammatory and cytoprotec-
tive effects after cold preservation and transplantation of lung grafts. Such ex vivo
treatment of lung grafts with carbon monoxide can minimize concerns associated
with carbon monoxide inhalation and might offer the opportunity to significantly
advance the application of carbon monoxide in the clinical setting.
L
ung transplantation (LTx) outcomes have improved significantly over the last
2 decades, and as a result, LTx is a viable option for many patients with end-
stage lung disease. However, although 1-year LTx survival rates have signif-
icantly improved to greater than 80%, 5-year survival rates remain poor, and both
short- and long-term outcomes lag significantly below those of most other solid organ
transplants (Organ Procurement and Transplantation Network).
During the procurement, transport, and transplantation process, donor lung grafts
are exposed to an obligatory period of cold ischemia with subsequent warm reperfu-
sion, leading to graft injury (ie, ischemia–reperfusion injury [IRI]). IRI is recognized
as a major determinant of primary graft dysfunction, which is a major complication in
clinical LTx and contributes significantly to early morbidity and mortality.1,2 Further-
more, the severity of IRI (and primary graft dysfunction) has been associated with the
risk of having bronchiolitis obliterans syndrome years later, suggesting that the injury
to lung grafts at the time of transplantation determines the fate of lung grafts or might
increase susceptibility to other events that contribute to subsequent graft dysfunc-
tion.2-5 Thus it is apparent that therapeutic strategies to mitigate IRI of lung allografts
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CO 5 carbon monoxide
COX 5 cyclooxygenase
HO 5 heme oxygenase
ICAM 5 intracellular adhesion molecule
IL 5 interleukin
iNOS 5 inducible nitric oxide synthase
IRI 5 ischemia–reperfusion injury
LTx 5 lung transplantation
RT–PCR 5 reverse transcription–polymerase chain
reaction
TNF-a 5 tumor necrosis factor a
UW 5 University of Wisconsin
could have significant clinical benefit. In addition, the effect
of IRI-mitigating strategies could be most profound in the
setting of use of marginal donors (and perhaps donation after
cardiac death). There has been an increased reliance on mar-
ginal donors to meet the growing demand for organ trans-
plantation, and these marginal organs are more susceptible
to cold IRI.6,7
A number of therapeutic modalities have been attempted
to attenuate IRI after organ transplantation in both experi-
mental and clinical studies.8,9 Among these potential thera-
peutic options, the application of carbon monoxide (CO),
a byproduct of the heme oxygenase (HO) system, might be
one of the most promising approaches.10 Indeed, we have
shown that CO delivered by means of inhalation at low con-
centrations to donors, recipients, or both mitigates lung IRI
associated with LTx in rats.11,12 In these studies CO demon-
strated potent anti-inflammatory and cytoprotective effects,
resulting in retention of lung endothelial ultrastructure and
improved graft function. Translating this strategy to the clinic
can be met with significant hurdles, however, given logistical
issues, concerns about exposure of health care workers to CO
during prolonged inhalational therapy, and concerns regard-
ing the adverse effects of formation of carboxyhemoglobin in
recipients. Limiting CO exposure to the graft during the cold
ischemic period through saturation of the perfusion and stor-
age solution might be a more clinically applicable strategy
and would minimize risk. In this study we tested the hypoth-
esis that delivery of CO to lung grafts through saturation of
the preservation solution used for flush and cold storage
would prevent lung IRI. We demonstrate that flushing and
storing lung allografts in preservation solution bubbled
with CO significantly protects lung grafts from IRI and sug-
gest that this approach might advance the application of CO
therapy in the clinical setting of LTx.
Materials and Methods
Animals
Inbred male Lewis (LEW, RT11) rats weighing 250 to 300 g were
purchased from Harlan Sprague Dawley, Inc (Indianapolis, Ind),1068 The Journal of Thoracic and Cardiovascular Surgery c Ocand maintained in laminar flow cages in a specific pathogen-free an-
imal facility at the University of Pittsburgh. Animals were fed a stan-
dard diet and provided water ad libitum. All procedures were
performed in accordance with the guidelines of the Institutional An-
imal Care and Use Committee at the University of Pittsburgh and the
National Research Council’s ‘‘Guide for the humane care and use of
laboratory animals.’’
CO Supplementation of Preservation Solution
For each experiment, a total of 50 mL of University of Wisconsin
(UW) solution (Viaspan; Du Pont, Wilmington, Del) was vigorously
bubbled at 4C for 5 minutes before use with compressed CO gas
mixed in air (5% or 100%; PRAXAIR, Danbury, Conn) under sterile
condition in a fume hood.13,14
Rat LTx
Orthotopic left LTx was performed in Lewis recipients from Lewis
donors by using a cuff technique, as previously described.11,12,15
Briefly, donor rats underwent tracheotomy and were mechanically
ventilated with a mixture of 100% oxygen and isoflurane, a positive
end-expiratory pressure of 2 cm H2O, a tidal volume of 10 mL/kg,
and a respiratory rate of 70 breaths/min. Donor animals were hepa-
rinized (300 U), and a laparosternotomy was performed. The entire
lung in the donor was isolated and excised. Lung grafts were flushed
through the main pulmonary artery (20 mL, 20 cm H2O) and stored
at 4C for 6 hours with either control UW solution or 5% or 100%
CO-bubbled UW (CO-UW) solution in an inflated state with 100%
oxygen. Recipient animals were intubated orotracheally and were
ventilated at the same settings as donors. A left thoracotomy was
performed, and the lung graft was implanted by using the cuff tech-
nique. Sham-operated animals underwent anesthesia and a thoracot-
omy. All recipients survived surgery and postoperative period until
they were sacrificed for end points.
Experimental Groups
Three groups of animals undergoing transplantation and one group
of sham-operated animals were studied. Animals in group 1 were
perfused and stored with control UW solution (control UW group).
In group 2 lung grafts were perfused and stored with 5% CO-UW
solution (5% CO-UW group). In the third group 100% CO gas
was used for bubbling of UW solution (100% CO-UW group).
Lung graft function
The function of lung grafts was assessed by determining the PO2 (iS-
TAT Portable Clinical Analyzer; iSTAT Corp, East Windsor, NJ) of
blood drawn from the pulmonary vein of the transplanted lung on
a fraction of inspired oxygen of 1.0 during mechanical ventilation.
With this technique, the resultant PO2 value is a reflection of only
graft gas exchange (sham group, n 5 6; control UW group, n 5
7; 5% CO-UW group, n 5 6; 100% CO-UW group, n 5 5).
Stain for infiltrating neutrophils and ED11
macrophages
Lung graft tissues procured 2 hours after reperfusion were fixed in
10% formalin, embedded in paraffin, and sectioned at a thickness
of 6 mm. Neutrophils in transplanted and contralateral (native) lungs
were stained with a naphthol AS-D chloroacetate esterase stainingtober 2008
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stained by means of immunohistochemistry for ED1, as described
previously.11 Positively stained cells were counted in a blinded fash-
ion in 20 high-power fields (3400 magnification) per section and
expressed as the number of cells per 0.1 mm2 (n5 5 for each group).
SYBR Green Real-time Reverse Transcription–
Polymerase Chain Reaction
The effect of CO on IRI-induced proinflammatory gene ex-
pression was assessed by means of SYBR green real-time re-
verse transcription–polymerase chain reaction (RT–PCR).
The time point was determined based on our previous obser-
vation that maximum inflammatory mediator expression oc-
curs 2 hours after reperfusion.12 Total RNA was extracted
from the lung grafts taken 2 hours after reperfusion with
the TRIzol reagent (Life Technologies, Inc, Grand Island,
NY), according to the manufacturer’s instructions. The
mRNA for interleukin (IL) 1b, IL-6, tumor necrosis factor
a (TNF-a), inducible nitric oxide synthase (iNOS), cycloox-
ygenase (COX) 2, intracellular adhesion molecule (ICAM) 1,
and glyceraldehyde-3-phosphate dehydrogenase were quan-
tified in duplicate by using SYBR Green 2-step, real-time
RT-PCR, as previously described.16 After removal of poten-
tially contaminating DNA with DNase I (Life Technologies),
3 mg of total RNA from each sample was used for reverse
transcription with oligo dT (Life Technologies) and Super-
script II (Life Technologies) to generate first-strand cDNA.
The PCR reaction mixture was prepared by using SYBR
green PCR Master Mix (PE Applied Biosystems, Foster
City, Calif), with the primers being designed according to
the literature or published sequences. Thermal cycling condi-
tions were 10 minutes at 95C to activate the Amplitaq Gold
DNA polymerase, followed by 40 cycles at 95C for 15 sec-
onds and 60C for 1 minute on an ABI PRISM 7000 Se-
quence Detection System (PE Applied Biosystems).
Expression of each gene was normalized with glyceralde-
hyde-3-phosphate dehydrogenase mRNA content (sham
group, n5 6; control UW group, n5 7; 5% CO-UW group,
n 5 6; 100% CO-UW group, n 5 5).
Data Analysis
Results are expressed as means6 standard error of the mean.
Statistical analysis was performed by using the Student t test
or analysis of variance where appropriate.
Results
Dose-dependent Solubility of CO in UW Solution
The solubility of CO in UW solution at 4C using various
CO concentrations was measured by using simplified gas
chromatography with a TRI lyzer.13,14 Bubbling preservation
solution with 5% CO for 5 minutes resulted in a CO concen-
tration of 39.1 6 2.4 mmol/L in solution. The soluble CO
concentration increased in a dose-dependent manner afterThe Journal of Thorbubbling with 50% or 100% CO (578.7 6 45.5 mmol/L
and 1025.3 6 78.9 mmol/L CO, respectively; Figure 1, A).
After bubbling with 100% CO for 5 minutes, the CO concen-
tration in solution was maintained during the cold storage pe-
riod, when the air phase was removed from the container. In
contrast, when UW with CO was allowed to contact air, sol-
uble CO in UW solution was quickly released into the air, and
CO levels returned to the basal level within a few hours (Fig-
ure 1, B). These results demonstrate that once CO is bubbled
into the preservation solution, the CO-bubbled solution must
be kept in the tightly sealed container with a secured lid
without an air layer to maintain a stable CO concentration
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Figure 1. A, The solubility of carbon monoxide (CO) in University
of Wisconsin solution at 4C after 5 minutes of bubbling with dif-
ferent concentrations of CO gas (n5 3 for each concentration). CO
solubility increases in a dose-dependent manner. B, Sequential
analysis of CO content in University of Wisconsin solution after
5 minutes of bubbling with 100% CO gas with or without secured,
air-tight lids. CO levels were maintained as long as 24 hours when
the container of University of Wisconsin solution was sealed
without an air phase (filled circles, n 5 3 for each time point).
However, CO concentrations decreased quickly when CO-bubbled
University of Wisconsin solution was exposed to air (open circles,
n 5 3).acic and Cardiovascular Surgery c Volume 136, Number 4 1069
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fashion.
Flush and Storage of Lung Grafts in 5% CO-UW
Solution Significantly Improves Graft Function
Lung graft function was assessed by determining PO2 levels
from the pulmonary veins of grafts at 2 hours after reperfu-
sion. The PO2 values from the graft pulmonary veins in
sham-operated animals were 305.3 6 13.1 mm Hg during
mechanical ventilation. Graft function was markedly im-
paired 2 hours after reperfusion in grafts stored in control
UW solution with PO2 levels that were less than 30% of
those seen in sham-operated animals (80.6 6 9.4 mm Hg).
Grafts flushed and stored in 5% CO-UW solution demon-
strated significantly improved graft function, with graft pul-
monary vein PO2 levels of 146.7 6 19.8 mm Hg (Figure 2,
A). The PCO2 levels in graft pulmonary vein blood were
not significantly different among groups at 2 hours after
reperfusion (sham group, 30.9 6 3.1 mm Hg; control UW
group, 35.3 6 3.6 mm Hg; 5% CO-UW group, 31.8 6 3.5
mm Hg; Figure 2, B).
5% CO-UW solution Significantly Reduces
Neutrophil and Macrophage Infiltration in Lung
Grafts
Neutrophil infiltration plays an important role in the inflam-
matory response of IRI through, among other processes, en-
hancing graft parenchyma damage by secreting proteolytic
enzymes, such as elastases,17,18 and physically impairing
the microcirculation. Although pulmonary neutrophils were
scarce in the sham-operated animals, a number of myeloper-
oxidase-positive cells were noted in pulmonary grafts after
cold storage in control UW solution and reperfusion, suggest-
ing that IRI caused rapid neutrophil infiltration in the grafts.
Flush and storage of grafts in CO-UW solution (5%) resulted
in significantly reduced neutrophil infiltration in the grafts at
2 hours after reperfusion (Figure 3).
Macrophages activated during the IRI process initiate
a cascade of events leading to the activation of the recipient
inflammatory system. and play a central role in lung
IRI.19,20 The number of ED11 macrophages in control UW
grafts increased to 52.7 6 1.2 per 0.1 mm2 2 hours after
reperfusion from 17.3 6 0.5 per 0.1 mm2 in sham-operated
animals. Lung grafts stored in CO-UW (5%) solution demon-
strated significantly reduced numbers of ED11 macrophages
(32.9 6 0.8 per 0.1 mm2, Figure 4).
5% CO-UW Solution Significantly Reduces
Expression of mRNA for Inflammatory Mediators
in Lung Grafts
Lung IRI results in the rapid production and release of numer-
ous proinflammatory mediators, as well as upregulation of
adhesion molecules.21,22 We evaluated the effect of CO sup-
plementation in the preservation solution on inflammatory1070 The Journal of Thoracic and Cardiovascular Surgery c Ocmediator expression in lung grafts after IRI with SYBR green
real-time RT-PCR. In grafts stored in control UW solution,
mRNA levels for the proinflammatory cytokines IL-6, IL-
1b, and TNF-a; the stress-induced molecules iNOS and
COX-2; and the adhesion molecule ICAM-1 were signifi-
cantly upregulated within 2 hours after reperfusion. Flush
and storage of grafts in 5% CO-UW solution significantly re-
duced peak levels of proinflammatory mediator mRNA by
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Figure 2. A, The pulmonary vein PO2 level of the sham-operated
animals was 305.3 6 13.1 mm Hg. The graft pulmonary vein PO2
level of the control University of Wisconsin (UW) group was mark-
edly reduced (80.66 9.4 mm Hg) at 2 hours after reperfusion. Lung
grafts in the 5% CO-UW group showed significantly higher PO2
levels compared with those of the control UW group at 2 hours af-
ter reperfusion (5% CO-UW group, 135.96 19.8 mm Hg; *P< .05 vs
control UW group). B, The PCO2 levels of graft pulmonary veins
were not significantly different between groups.tober 2008
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control UW solution (Figure 5).
100% CO-UW Solution Does not Provide Further
Improvement in Graft Function After IRI
To evaluate whether treatment with a higher concentration of
CO might provide additional graft protection compared with
5% CO, we investigated the effects of supplementation of the
preservation solution with 100% CO (resulting in a 25 times
higher concentration of CO in solution). Although flush and
storage of grafts with UW solution bubbled with 100% CO
improved graft function compared with that seen in control
grafts, it did not improve graft function beyond that achieved
with 5% CO-UW solution: PO2 levels of graft pulmonary vein
Figure 3. Neutrophil infiltration of lung grafts 2
hours after reperfusion. Prolonged cold storage
and reperfusion after transplantation resulted in
massive infiltration of myeloperoxidase-positive
neutrophils in control grafts. Flush and storage
of lung grafts in University of Wisconsin (UW) so-
lution bubbledwith 5% carbon monoxide (CO) sig-
nificantly reduced the number of neutrophils seen
in the graft (*P < .05 vs control UW solution).
(Original magnification3400). PMN, Polymorpho-
nuclear neutrophil.
Figure 4. ED11 macrophage recruitment to lung
grafts. The number of infiltrating alveolar ED11
macrophages remarkably increased in control
University of Wisconsin (UW) solution at 2 hours
after reperfusion. Carbon monoxide (CO)–UW
(5%) solution significantly reduced macrophage
infiltration (*P < .05 vs control UW group). (Orig-
inal magnification 3400).The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 1071
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Figure 5. Intragraft mRNA levels of inflammatory
mediators. mRNA for the proinflammatory cyto-
kines interleukin 6 (IL-6), interleukin 1b (IL-1b),
and tumor necrosis factor a (TNF-a); the stress-
induced molecules inducible nitric oxide syn-
thase (iNOS) and cyclooxygenase 2 (COX-2); and
the adhesion molecule intercellular adhesion
molecule 1 (ICAM-1) were rapidly upregulated
within 2 hours after reperfusion in control ani-
mals. 5% Carbon monoxide (CO)–University of
Wisconsin (UW) solution significantly reduced
expression of these inflammation-related mole-
cules (*P < .05 vs the control UW group).stored in 100% CO-UW solution were 147.86 15.8 mm Hg,
whereas those of 5% CO-UW solution were 146.7 6 19.8
mm Hg; (Figure 6, A).
Effects of 100% CO-UW Solution on Inflammatory
Cellular Recruitment
Although 5% CO-UW solution had potent effects on the pre-
vention of graft inflammatory cellular infiltration, the number
of neutrophils in the grafts stored in 100% CO-UW solution
was not different from that seen in grafts stored in control UW
solution (Figure 6, B). Similarly, the number of ED11macro-
phages in the grafts stored in 100% CO-UW solution was
47.16 1.2 per mm2, which was significantly more than those
seen in grafts stored in 5% CO-UW solution (Figure 6, C).
Alteration of mRNA Levels for Inflammatory
Mediators With 100% CO-UW Solution
The anti-inflammatory effects of 100% CO-UW solution
were also evaluated by determining mRNA expression for in-
flammatory mediators. As previously demonstrated, 5% CO-
UW solution significantly reduced the peak levels of mRNA
expression of inflammatory mediators. The effects of 100%
CO-UW solution were comparable with those of 5% CO-
UW solution in inhibition of iNOS, COX-2, and ICAM-11072 The Journal of Thoracic and Cardiovascular Surgery c Olevels. In contrast, 100% CO-UW solution did not reduce
mRNA levels of IL-6, IL-1b, and TNF-a compared with those
seen in the grafts stored in control UW solution (Figure 7).
Discussion
CO has been increasingly recognized as a pleiotropic mole-
cule with many properties, including a role in fundamental
cell-signaling processes, as well as cytoprotective and anti-in-
flammatory properties that mitigate IRI. Although basal low
levels of CO are produced endogenously in mammalian tis-
sues through the action of the enzyme HO on heme, in the set-
ting of oxidative stress of transplantation (as well as other
scenarios), numerous strategies have been used to manipulate
this system to mitigate IRI in various organ types. The use of
chemical HO inducers,23 gene therapy to overexpress HO,24
and the delivery of CO directly by means of inhalation16,25
or the use of CO-releasing molecules26,27 are therapeutic strat-
egies that have all demonstrated efficacy in experimental
transplantation models of IRI. Although many or all of these
therapeutic approaches might prove clinically feasible, they
all create logistic difficulties, as well as (in the case of CO in-
halation delivery) the potential for exposure of patients and
health care workers to toxic doses of CO. To simplify delivery
of CO and to avoid recipient exposure to higher doses, in thectober 2008
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Figure 6. The effects of a higher concentration of carbon monox-
ide (CO) on pulmonary graft function and cellular infiltration. A,
Graft function, as assessed by means of graft oxygenation, was
no different between grafts flushed and stored with 5% CO–Uni-
versity of Wisconsin (UW) solution compared with those flushedThe Journal of Thorcurrent study we hypothesized and evaluated whether deliv-
ery of CO to lung grafts through a CO-saturated flush and per-
fusate solution would mitigate IRI in experimental LTx. Our
data demonstrate that flush and cold storage of lung grafts in
preservation solution bubbled with 5% CO diminishes IRI, re-
sulting in significantly improved graft function and reduced
graft inflammation. Notably, the therapeutic effect observed
in this study is comparable with the effect we observed in pre-
vious studies in which low-dose CO (250 ppm) was delivered
by means of inhalation to both lung donors and recipients (be-
ginning before transplantation and continuing after transplan-
tation in recipients). Another important aspect of the current
study is the demonstration that CO is rapidly (over hours) re-
leased from solution if an air–solution interface exists. Thus
protocols using this strategy must use airtight containers
and avoid an air–solution interface.
We have previously shown that storing and flushing intes-
tinal grafts13 and kidney grafts28 in CO-supplemented UW so-
lution prevents the graft deterioration associated with IRI. In
our previous studies13,28 we applied 5% CO-UW solution
(achieving a CO concentration of 40.6 mmol/L) based on the
results of previous studies using CO-releasing molecules,
showing that CO concentrations of 10 to 50 mmol/L in perfus-
ate provided the best results in protection of cardiomyocytes26
and the renal vascular system29 against oxidative stress. In this
study we provide evidence that higher concentrations of CO in
solution (achieved through bubbling UW solution with 100%
CO) do not enhance the protective effects seen with 5% CO
gas. This might be an important step for the clinical applica-
tion of CO as an additive to the preservation solution to deter-
mine the most appropriate CO concentration in solution. Our
previous work demonstrated that a CO concentration of 2.15
mmol/L (bubbling with 0.1% CO gas) did not improve intes-
tinal cold IRI.13 Based on these results, we will further opti-
mize CO concentrations in preservation solutions in future
experiments to establish an optimized, clinically applicable,
effective, and safe ex vivo CO delivery method.
Although the mechanisms involved in the protection af-
forded by ex vivo CO delivery are not fully elucidated, we
postulate one possible mechanism of the binding activity of
CO with heme protein. CO possesses a strong affinity to
with 100% CO-UW solution. Both groups demonstrated improved
graft function compared with that seen in control grafts. B, The
number of infiltrating neutrophils was significantly reduced
when the grafts were stored in UW solution with supplementation
of 5% CO gas. However, the effects of 100% CO-UW solution were
marginal in preventing neutrophil recruitment (*P< .05 vs control
UW solution, #P < .05 vs 5% CO-UW solution). C, Although 5%
CO-UW solution significantly reduced the number of ED11
macrophages in the grafts, 100% CO-UW solution did not alter
macrophage recruitment in the graft lung 2 hours after reperfusion
(*P< .05 vs control UW solution, #P< .05 vs 5% CO-UW solution).acic and Cardiovascular Surgery c Volume 136, Number 4 1073
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Figure 7. Real-time RT-PCR analysis for inflam-
matory mediators 2 hours after reperfusion. The
upregulation of mRNA for inflammatory mediators
was significantly inhibited when lung grafts
were perfused and stored in University of Wis-
consin (UW) solution with 5% carbon monoxide
(CO). The effects of 100% CO had comparable ef-
fects in preventing interleukin 6 (IL-6), inducible
nitric oxide synthase (iNOS), cyclooxygenase 2
(COX-2), and intercellular adhesion molecule 1
(ICAM-1) mRNA upregulation; however, the anti-
inflammatory effects of 100% CO were marginal
on tumor necrosis factor a (TNF-a) and interleu-
kin 1b (IL-1b) mRNA levels (*P < .05 vs control
UW solution, #P < .05 vs 5% CO-UW solution).the heme moiety of heme proteins and potentially influences
the biologic behaviors of heme proteins.30,31 Bysani and col-
leagues as well as others have demonstrated that cytochrome
P450, an abundant heme protein in the lung, degrades during
IRI and release of heme.32-34 Free heme released from heme
proteins, such as cytochrome P450, during IRI not only pro-
motes peroxidation of the lipid membranes of the cells35,36
but also activates adhesion molecules, leading to massive cel-
lular infiltration and increases in vascular permeability, con-
tributing to the pathogenesis of local inflammatory
processes.36-39 In addition, free heme can be a major source
of iron, which participates in the generation of more detri-
mental hydroxyl radicals from hydrogen peroxide through
the Fenton reaction.40,41 We have shown that 5% CO-UW so-
lution could prevent degradation of cytochrome P450 and
prevent heme/iron release during IRI in the kidney.28 Our ob-
servations in this study might support the role of CO in bind-
ing heme protein and inhibiting heme/iron-derived graft
injuries. Although we do not have a clear explanation why
100% CO did not prevent IRI, we postulate that high concen-
trations of CO might be harmful by completely inhibiting the
enzymatic function of remaining cytochrome P450, altering
other critical heme proteins required to maintain cell viabil-
ity, or releasing CO into the recipient circulation after trans-
plantation. In addition, Taille and associates42 showed that
CO modulates redox signaling by interacting with the heme
moiety of NAD(P)H oxidase, the respiratory chain, or both.
In summary, our results demonstrate that the addition of
CO to the preservation solution used for flush and cold storage
reduces IRI in lung grafts, resulting in improved graft function
and reduced inflammation. This approach is straightforward,
could be easily adapted in the clinic, and could potentially
have a positive effect on patient care in the early posttrans-
plantation period and improve long-term outcomes.
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